abbvie-singapore

AbbVie opens its $300 million manufacturing plant in Singapore

pharmafile | September 29, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore 

AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to employ more than 250 new employees, of whom most will be hired within the country. The base adds to the 13 other locations AbbVie holds in the United States, Europe and Puerto Rico.

Azita Gerhardt, senior vice-president of operations, released a statement regarding the plant saying: “Today, with the opening of the first phase of our Singapore facility, we will further strengthen our manufacturing capabilities and continue to enhance our support of AbbVie’s pipeline in the therapeutic areas of oncology and women’s health for patients around the world.”

Marc O’Donoghue, the site director, highlighted the reasons that Singapore was chosen as country – suggesting that it was based upon its “robust infrastructure” and “highly educated and skilled workforce…Our presence in Singapore established AbbVie’s footprint in Asia and provides geographic balance in AbbVie’s manufacturing network to ensure continuity of supply”.

The process was welcomed by S Iswaran, Minister for Trade and Industry. He commented that “The Biomedical manufacturing cluster is the second largest contributor to Singapore’s manufacturing sector, accounting for close to 20% of the sector’s value added…For instance, our biomedical manufacturing output has more than quadrupled from S$6.3 billion in 2000 to approximately S$27 billion in 2014”.

Ben Hargreaves

Related Content

Medincell and AbbVie enter agreement for development of next-generation injectables

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …

AbbVie to acquire Landos Biopharma for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …

AbbVie and Tentarix collaborate on oncology and immunology treatments

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on …

Latest content